Fecal Calprotectin and Organic Gastrointestinal Disease: A Systematic Review
Authors:
Open Access
- 11 September 2023
- journal article
- review article
- Published by Springer Nature in Cureus
- Vol. 15 (9) , e45019
Abstract
This review aimed to assess the diagnostic utility of fecal calprotectin (FCP) for identifying organic gastrointestinal disease (OGID) in patients undergoing colonoscopy for gastrointestinal discomfort or active progression of inflammatory bowel disease (IBD). Studies published between January 2013 and December 2022 evaluating the clinical efficacy of FCP for differentiating OGID against functional gastrointestinal disease (FGID) were identified using PubMed, Cochrane, and Scopus databases. Clinical diagnostic studies involving individuals with lower gastrointestinal symptoms; using FCP as a diagnostic biomarker either in primary, secondary, or tertiary healthcare centers conducted either prospectively or retrospectively using stool samples (index test), contrasting FCP with a reference test, such as colonoscopy, or endoscopy, and assessed using enzyme-linked immunosorbent assay were reviewed. The included studies were subjected to the revised Quality Assessment of Diagnostic Accuracy Studies for assessing the methodological quality by two independent authors. An initial literature search yielded 545 articles rendering 417 records after removing the duplicate records. After reading the abstracts and titles, 89 articles were eligible for full-text screening. The qualitative synthesis resulted in 20 articles. The efficient use of FCP for differentiating IBD from irritable bowel syndrome was investigated in 15 studies. Two of the included studies assessed the diagnostic ability of FCP to distinguish OGID from FGID, two studies utilized patients with ulcerative colitis, and one study involved patients with Crohn’s disease. Overall study quality was high for 65% of studies, moderate for 25% of studies, and low for 10% of studies. The review outlined the diagnostic accuracy of non-invasive FCP assessment for OGID in various clinical scenarios and in individuals of various ages. FCP is used as a tool for screening and monitoring in clinical practice for determining the need of further comprehensive investigations, thereby reducing the redundant use of invasive techniques.Keywords
This publication has 41 references indexed in Scilit:
- Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndromeMolecular Medicine Reports, 2014
- Faecal calprotectin for differentiating between irritable bowel syndrome and inflammatory bowel disease: a useful screen in daily gastroenterology practiceFrontline Gastroenterology, 2014
- Utility of faecal calprotectin in inflammatory bowel disease (IBD): what cut-offs should we apply?Frontline Gastroenterology, 2014
- Fecal calprotectin, MMP-9, and human beta-defensin-2 levels in pediatric inflammatory bowel diseaseInternational Journal of Colorectal Disease, 2013
- Diagnostic accuracy and clinical application of faecal calprotectin in adult patients presenting with gastrointestinal symptoms in primary careScandinavian Journal of Gastroenterology, 2013
- Faecal calprotectin concentrations in gastrointestinal diseasesJournal of International Medical Research, 2013
- Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood LeukocytesInflammatory Bowel Diseases, 2013
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Validation and clinical significance of a new calprotectin rapid test for the diagnosis of gastrointestinal diseasesInternational Journal of Colorectal Disease, 2008
- Diagnostic performance of rapid tests for detection of fecal calprotectin and lactoferrin and their ability to discriminate inflammatory from irritable bowel syndromeClinical Chemistry and Laboratory Medicine (CCLM), 2008